Ф А 2.2.1-36-367

MINISTRY OF HEALTH OF UKRAINE
NATIONAL UNIVERSITY OF PHARMACY
Pharmaceutical Faculty
Department of Pharmacology and Clinical Pharmacy

QUALIFICATION WORK

on the topic: «**POLYPRAGMASIA AND HYPERTENSION: EVALUATING DRUG-DRUG INTERACTIONS AND THE PHARMACIST'S ROLE IN RISK REDUCTION**»

Prepared by: higher education graduate of group
Фм21(4,10д) англ-01
specialty 226 Pharmacy, industrial pharmacy
educational and professional program Pharmacy
Ghizlane KEBAILI
Supervisor: associate professor of higher education institution
of department of pharmacology and clinical pharmacy, PhD,
associate professor Inna OTRISHKO
Reviewer: head of the department of clinical pharmacology
of the Institute for Advanced Training of Pharmacy Specialists
of the National University of Pharmacy, DSc,
professor Yaroslava BUTKO

Kharkiv – 2026

ANNOTATION

The qualification work is devoted to the study of drug-drug interactions among hypertensive patients, their clinical consequences, and the evaluation of pharmacist interventions in identifying and managing these interactions to improve patient safety and therapeutic outcomes.

Qualification work is presented on 61 pages of typewritten text, consists of summary, introduction, 3 chapters, conclusions, references. The work is illustrated with 20 tables, 6 figures. The list of references contains 36 resources.

Key words: hypertension, drug-drug interactions, polypharmacy, pharmacist intervention, medication therapy management, patient safety, antihypertensive medications, clinical pharmacy.

АНОТАЦІЯ

Кваліфікаційна робота присвячена вивченню лікарських взаємодій серед пацієнтів з артеріальною гіпертензією, їх клінічних наслідків, а також оцінці фармацевтичних утручань у виявленні та управлінні цими взаємодіями з метою підвищення безпеки пацієнтів та ефективності терапевтичних результатів.

Кваліфікаційна робота викладена на 61 сторінці машинописного тексту, складається з реферату, вступу, 3 розділів, висновків, списку літератури. Робота ілюстрована 20 таблицями, 6 рисунками. Список літератури містить 36 джерел.

Ключові слова: артеріальна гіпертензія, лікарські взаємодії, поліпрагмазія, фармацевтичне втручання, управління медикаментозною терапією, безпека пацієнтів, антигіпертензивні лікарські засоби, клінічна фармація.

TABLE OF CONTENTS

INTRODUCTION 6

CHAPTER 1 MODERN PRESENTATION ABOUT POLYPHARMACY IN HYPERTENSION (LITERATURE REVIEW)..... 8

1.1. Hypertension: definition, prevalence, and complications..... 8

1.2. Pharmacological management of hypertension..... 9

1.3. Polypharmacy: definition, causes, prevalence in hypertensive patients.. 11

1.4. Drug–drug interactions in hypertensive patients: mechanisms, types, and classifications…… 12

1.5. Clinical consequences of DDIS in hypertension management…….. 20

1.6. Pharmacist’s role in medication review and risk reduction…… 22

Conclusions of chapter 1……... 24

CHAPTER 2 MATERIALS AND METHODS..... 26

Conclusions of chapter 2……... 29

CHAPTER 3 EVALUATING DRUG–DRUG INTERACTIONS AND PHARMACIST’S INTERVENTIONS (EXPERIMENTAL PART)..... 30

3.1. Survey of hypertensive patients: demographics, medication use…… 30

3.2. Prevalence and types of polypharmacy……... 37

3.3. Detection and classification of drug–drug interactions…….. 44

3.4. Pharmacist's recommendations to manage or prevent DDIs…….. 49

3.5. Impact of pharmacist interventions: acceptance rate and outcomes…… 55

3.6. Practical recommendations for improving DDIs management in hypertensive patients……. 56

Conclusions of chapter 3……... 59

CONCLUSIONS 61

REFERENCES 62

LIST OF ABBREVIATIONS

ACE	–	Angiotensin-Converting Enzyme
ACEIs	–	Angiotensin-Converting Enzyme Inhibitors
AF	–	Atrial Fibrillation
AKI	–	Acute Kidney Injury
ARBs	–	Angiotensin II Receptor Blockers
ARNIs	–	Angiotensin Receptor–Neprilysin Inhibitors
ASA	–	Acetylsalicylic Acid
AV	–	Atrioventricular
BID	–	*Bis in die* (Twice Daily)
BP	–	Blood Pressure
bpm	–	Beats Per Minute
BUN	–	Blood Urea Nitrogen
CAD	–	Coronary Artery Disease
CCBs	–	Calcium Channel Blockers
CI	–	Confidence Interval
CKD	–	Chronic Kidney Disease
COX	–	Cyclooxygenase
CPK	–	Creatine Phosphokinase
CV	–	Cardiovascular
CVD	–	Cardiovascular Disease
CYP3A4	–	Cytochrome P450 3A4
CYP450	–	Cytochrome P450 Enzyme System
DBP	–	Diastolic Blood Pressure
DDIs	–	Drug–Drug Interactions
DM2	–	Diabetes Mellitus Type 2
DOAC	–	Direct Oral Anticoagulant
DSc	–	Doctor of Science
eGFR	–	Estimated Glomerular Filtration Rate
GERD	–	Gastroesophageal Reflux Disease
GI	–	Gastrointestinal

HCTZ	–	Hydrochlorothiazide
HF	–	Heart Failure
HICs	–	High-Income Countries
HLD	–	Hyperlipidemia
HR	–	Heart Rate / Hazard Ratio
HTN	–	Hypertension
INN	–	International Nonproprietary Name
INR	–	International Normalized Ratio
IU	–	International Units
KPI	–	Key Performance Indicator
LFTs	–	Liver Function Tests
LMICs	–	Low- and Middle-Income Countries
MI	–	Myocardial Infarction
mmHg	–	Millimeters of Mercury
MTM	–	Medication Therapy Management
NSAIDs	–	Nonsteroidal Anti-Inflammatory Drugs
OR	–	Odds Ratio
OTC	–	Over-the-Counter
PDE-5	–	Phosphodiesterase Type 5
PhD	–	Doctor of Philosophy
PRN	–	*Pro re nata* (As Needed)
RAAS	–	Renin–Angiotensin–Aldosterone System
RR	–	Relative Risk
SBP	–	Systolic Blood Pressure
SCr	–	Serum Creatinine
SD	–	Standard Deviation
SGLT2	–	Sodium–Glucose Cotransporter 2
SMOBP	–	Self-Monitoring of Blood Pressure
ULN	–	Upper Limit of Normal
VTE	–	Venous Thromboembolism
WHO	–	World Health Organization

INTRODUCTION

Relevance of the topic. Hypertension remains a major global health concern, affecting roughly 1.28 billion adults aged 30–79 worldwide, with most cases occurring in low- and middle-income countries. Despite its widespread prevalence, only about 42% of diagnosed individuals receive treatment, and merely 21% achieve adequate blood pressure control, highlighting serious gaps in both detection and care. The burden is especially pronounced in the WHO South-East Asia and Western Pacific regions, where both prevalence and case numbers have risen markedly in recent decades [1].

Treating hypertension often involves multiple medications, particularly when patients also have conditions such as diabetes, chronic kidney disease, or cardiovascular disorders. Polypharmacy – commonly defined as the concurrent use of five or more drugs – occurs in approximately 23.7% of individuals with hypertension, compared to just 4.7% in the general population. Higher socioeconomic status and the presence of several comorbidities further increase the likelihood of polypharmacy. Among the various antihypertensive agents prescribed, calcium channel blockers are some of the most frequently used [2].

The use of numerous medications significantly increases the likelihood of drug–drug interactions (DDIs), which can reduce treatment effectiveness, raise the risk of adverse drug reactions, and lead to negative clinical outcomes. Research indicates that more than 80% of hypertensive patients experiencing polypharmacy encounter at least one potential DDI, most commonly of moderate severity. Pharmacodynamic interactions – such as enhanced blood pressure–lowering effects or increased risk of kidney toxicity – are frequent and often involve medications like ACE inhibitors, beta-blockers, and diuretics [2, 3, 4].

Pharmacists play an essential role in mitigating these risks by identifying, preventing, and managing DDIs through medication reviews, patient education, and collaboration with prescribers. Their involvement improves medication safety and adherence, ultimately contributing to more effective hypertension management [2, 3].

The aim of the study. The aim of the thesis is to estimate the prevalence and drug–drug interaction categorizations among hypertensive patients under polypharmacy and investigate the effect of pharmacist counseling in reducing the risk.

The objectives of the study. Objectives of the work are the following:

1. In order to evaluate the prevalence and classification of DDIs among polypharmacy hypertensive patients.

2. In order to recognize the most prevalent and clinically relevant DDIs among this population.

3. In an attempt to evaluate the impact of pharmacy-led activities in reducing the incidence and consequences of DDIs.

4. To study the role of pharmacist in in the detection and management of drug–drug interactions among hypertensive patients.

5. Practical recommendations for improving the effectiveness and safety of drug therapy among polypharmacy hypertensive patients.

Object of research: drug–drug interactions among hypertensive patients.

Subject of research: the role of the pharmacist in the detection and management of drug–drug interactions among hypertensive patients.

Research methods. Literature review, patient questionnaires, intervention from the pharmacist, and statistical examination.

Structure and scope of qualification work. Qualification work is presented on the 61 pages of typewritten text, consists of summary, introduction, 3 chapters, conclusions, references. The work is illustrated with 30 tables, 6 figures. The list of literature contains 36 references.

CHAPTER 1
MODERN PRESENTATION ABOUT POLYPHARMACY IN HYPERTENSION (LITERATURE REVIEW)

1.1. Hypertension: definition, prevalence, and complications

Hypertension is defined as a sustained elevation in blood pressure, specifically a systolic blood pressure (SBP) of ≥140 mm Hg and/or a diastolic blood pressure (DBP) of ≥90 mm Hg, or the use of antihypertensive therapy to maintain blood pressure control [4]. In 2017, the American College of Cardiology and the American Heart Association updated their guidelines, lowering the diagnostic threshold to SBP ≥130 mm Hg or DBP ≥80 mm Hg, based on evidence showing that stricter blood pressure targets reduce cardiovascular risk [5].

As a major global health concern, hypertension affects more than 1.3 billion adults worldwide [4, 6]. Its prevalence has risen substantially in recent decades, particularly in low- and middle-income countries (LMICs), which account for nearly 75% of all cases [5, 6]. For example, between 2000 and 2010, the prevalence in LMICs increased from 23.8% to 31.5%, whereas in high-income countries (HICs) it declined slightly from 31.1% to 28.5% [5]. By 2019, the global age-standardized prevalence among individuals aged 30–79 years was estimated at around 31% [6]. Age plays a crucial role, with more than 60% of people over 60 years old affected by hypertension worldwide [4, 5].

Poorly controlled hypertension can cause serious damage to vital organs. It contributes to arterial stiffening, which reduces blood and oxygen flow to the heart, potentially leading to angina, myocardial infarction, heart failure, and arrhythmias that may result in sudden death [4]. It also increases the risk of stroke by impairing or obstructing cerebral blood vessels [4], and can lead to kidney damage and eventual renal failure [4]. These complications are particularly severe in LMICs due to lower rates of diagnosis, treatment, and effective control [6].

Several factors significantly heighten the risk of complications, including

smoking, poor adherence to treatment, and longer duration of the disease [7]. For instance, smokers face more than a threefold increase in complication risk compared to nonsmokers, while individuals who do not follow their prescribed treatment have over eight times greater risk [7].

1.2. Pharmacological management of hypertension

The aim of drug therapy for hypertension is to bring blood pressure down to recommended target levels, thereby minimizing the risk of cardiovascular, renal, and cerebrovascular complications. Treatment approaches are guided by both international and national clinical guidelines, which have been updated in recent years to reflect new evidence and current best practices.

First-line antihypertensive drug classes

Current guidelines are to initiate treatment with one or more of the following key drug classes, based on patient profile and comorbidities [8, 9, 10]:

- angiotensin-converting enzyme inhibitors (ACEIs);
- angiotensin II receptor blockers (ARBs);
- calcium channel blockers (CCBs);
- thiazide or thiazide-like diuretics;
- beta-blockers (recommended as first-line in some guidelines, especially if there are specific indications such as ischemic heart disease or heart failure).

The major antihypertensive drug classes and indications are presented in Table 1.1.

Table 1.1

Major antihypertensive drug classes and indications

Drug Class	Examples	Typical Indications
ACEIs	Enalapril, Lisinopril	Heart failure, diabetes, CKD, post-MI
ARBs	Losartan, Valsartan	ACEI intolerance, diabetes, CKD
CCBs	Amlodipine, Nifedipine	Elderly, isolated systolic hypertension

Continued Table 1.1

Thiazide diuretics	Hydrochlorothiazide	Black patients, elderly, volume overload
Beta-blockers	Bisoprolol, Metoprolol	Post-MI, arrhythmia, heart failure, pregnancy, younger patients

Treatment Initiation and Combination Therapy

- *Monotherapy* is suitable for patients with mild hypertension or low cardiovascular risk.
- *Dual therapy* (generally as a combination pill) is indicated for most patients, particularly those with BP ≥20/10 mm Hg above goal or high cardiovascular risk [8, 9, 11].
- *Preferred combinations:*
  - ACEI or ARB + CCB;
  - ACEI or ARB + thiazide diuretic;
  - CCB + thiazide diuretic (uncommon).

Treatment Targets

- *General population*: target BP <140/90 mm Hg.
- *High-risk patients* (e.g., diabetes, CKD, CVD): The lower targets can be applied, i.e., <130/80 mm Hg, if tolerated [8, 9].

Special Considerations

- *Resistant Hypertension*: in those patients in whom BP remains elevated on three-drug regimens (including a diuretic), the addition of a mineralocorticoid receptor antagonist (e.g., spironolactone) is recommended, in the absence of contraindications [8].
- *Comorbidities*: drug selection should be tailored to comorbid conditions (e.g., ACEIs/ARBs for diabetes or CKD; beta-blockers for ischemic heart disease).
- *Compliance*: single-pill treatment improves BP control and adherence.

Modern Developments

- *Innovative substances*: new drug classes, including angiotensin receptor-neprilysin inhibitors (ARNIs) and sodium-glucose co-transporter 2 (SGLT2) inhibitors, are now being used in specific hypertensive groups, especially those with heart failure or diabetes [11].
- *Device-based therapies*: renal denervation and baroreceptor stimulation are being studied for resistant hypertension but are not yet standard of care [8].

The main recommendations are presented in Table 1.2.

Table 1.2

Key recommendations

Recommendation	Evidence Level
Initiate with ACEI, ARB, CCB, or thiazide	High
Prefer dual therapy in most patients	High
Use single-pill combinations where possible	High
Add spironolactone for resistant hypertension	Moderate
Tailor therapy to comorbidities	High

1.3. Polypharmacy: definition, causes, prevalence in hypertensive patients

Polypharmacy is typically described as the simultaneous use of five or more medications, including prescription drugs, over-the-counter medicines, and complementary therapies. This definition is widely applied in contemporary clinical research involving patients with hypertension [12, 13].

Several factors contribute to the development of polypharmacy in individuals with hypertension:

• *Multimorbidity*: Patients with hypertension often have additional conditions such as diabetes, dyslipidemia, and chronic kidney disease, each requiring further pharmacological treatment [14].

• *Guideline-driven treatment*: Modern hypertension management frequently recommends combination therapy to achieve optimal blood pressure control, increasing the total number of medications used.

• *Aging*: As people grow older, both hypertension and other chronic diseases become more common, which raises the likelihood of multiple drug use [14].

• *Fragmented healthcare*: Consulting multiple specialists may lead to overlapping or unnecessary prescriptions [12].

Prevalence among hypertensive patients

Available data indicate that the occurrence of polypharmacy in hypertensive populations varies depending on the setting and patient group. For example, a multicenter study conducted in Saudi Arabia in 2023 found that about 21% of hypertensive patients in primary care were exposed to polypharmacy, defined as taking five or more medications daily [13]. In contrast, hospital-based studies in Europe report much higher rates, with approximately 81% of hospitalized hypertensive patients meeting the criteria, particularly among older adults with multiple comorbidities [14]. Overall, the likelihood of polypharmacy increases significantly with greater disease complexity and the presence of additional chronic conditions [13, 14].

1.4. Drug–drug interactions in hypertensive patients: mechanisms, types, and classifications

Drug–drug interactions (DDIs) occur when the effect of one medication is modified by the simultaneous use of another, potentially leading to increased therapeutic action, greater toxicity, or reduced effectiveness. These interactions are particularly important in patients with hypertension, where polypharmacy is common; studies show that up to 81% of older hypertensive individual's experience at least one potential DDI, resulting in significant clinical and economic consequences [15, 16].

Mechanisms of drug–drug interactions in hypertension

DDIs in hypertensive patients can be broadly classified into two main

categories [15, 16, 17]:

Pharmacokinetic interactions

These involve changes in drug absorption, distribution, metabolism, or excretion, ultimately influencing drug concentrations in the body and their clinical effects.

• Absorption: Factors such as altered gastric pH, drug binding (chelation), or changes in gastrointestinal motility can affect how drugs are absorbed. For example, proton pump inhibitors may reduce the absorption of pH-dependent antihypertensive agents, while calcium supplements can bind certain drugs and lower their bioavailability [16, 17].

• Distribution: Interactions may occur through displacement from plasma protein binding sites or altered tissue distribution. A classic example is aspirin displacing warfarin from albumin, increasing the free fraction of warfarin and raising bleeding risk [16, 17].

• Metabolism (CYP450 system): One of the most clinically significant mechanisms involves cytochrome P450 enzymes, particularly CYP3A4. Medications such as diltiazem and verapamil inhibit this enzyme and can significantly affect the metabolism of other drugs. For instance, verapamil can increase digoxin levels by 50–75% by inhibiting both CYP3A4 and P-glycoprotein, substantially elevating the risk of toxicity [16, 17].

• Excretion: Interactions may also alter renal or hepatic elimination. Spironolactone can reduce digoxin clearance by about 25%, while thiazide diuretics may decrease lithium excretion, increasing the risk of toxicity [16, 17].

Pharmacodynamic interactions

These account for about 37.3% of DDIs in hypertensive patients and occur when drugs influence the same physiological systems or receptors without changing drug concentrations [15, 16].

• Additive hypotensive effects: combining antihypertensive agents from different classes can produce enhanced blood pressure–lowering effects. For example, ACE inhibitors used with calcium channel blockers may provide greater cardiovascular benefit than either alone. However, combining beta-blockers with

calcium channel blockers can lead to excessive hypotension and bradycardia, requiring careful monitoring [16, 18].

• Antagonistic effects: nonsteroidal anti-inflammatory drugs (NSAIDs) are a major cause of antagonistic interactions. By inhibiting prostaglandin synthesis, they can reduce the effectiveness of most antihypertensive drugs – especially ACE inhibitors, ARBs, and diuretics – leading to sodium retention, reduced vasodilation, and poorer blood pressure control [15, 16, 17].

• Electrolyte imbalances: concurrent use of medications affecting electrolyte balance can be dangerous. For instance, combining ACE inhibitors or ARBs with potassium-sparing diuretics may result in severe hyperkalemia (serum potassium >5.5 mEq/L), while using thiazide and loop diuretics together can cause significant hypokalemia [16, 17].

Prevalence and clinical importance

Recent studies highlight high levels of polypharmacy among patients with hypertension. Older hypertensive individuals take an average of 8.2 medications daily, with 81% meeting the definition of polypharmacy (≥5 drugs), compared to 65% among normotensive individuals. The likelihood of DDIs increases sharply with each additional medication, with risk rising exponentially as more drugs are added [15, 16].

Key risk factors for DDIs include [15, 16, 17]:

• advanced age (particularly over 65 years);

• male sex (odds ratio approximately 2.5);

• polypharmacy (use of more than four medications increases DDI risk by about 400%);

• presence of multiple comorbid conditions (e.g., diabetes, cardiovascular disease, chronic kidney disease);

• impaired renal function, which reduces drug clearance.

Major interactions between antihypertensive drug classes are summarized in Table 1.3, while interactions between drugs and coexisting diseases are outlined in Table 1.4.

Table 1.3

Antihypertensive drug interactions by class

	Drug Combination	Interaction Type	Mechanism	Clinical Effect	Incidence/ Severity	Management
ACE inhibitor interactions	Enalapril + Aspirin [15]	Pharmacodynamic	Prostaglandin inhibition	Reduced antihypertensive effect (20-30% decrease)	Most common DDI (28.4%)	Monitor BP closely, consider alternatives
	Enalapril + Diclofenac [16]	Pharmacodynamic	COX inhibition + nephrotoxicity	Acute renal failure risk, reduced efficacy	High risk in elderly	Avoid combination
	Enalapril + Spironolactone[16]	Pharmacodynamic	Dual potassium retention	Hyperkalemia risk (K+ >5.5 mEq/L)	15-20% of combinations	Weekly electrolyte monitoring
	Enalapril + Furosemide [16]	Pharmacodynamic	Additive hypotension + electrolyte loss	Excessive hypotension, hyponatremia	Common in heart failure	Monitor BP and electrolytes

	ACE inhibitor + ARB [17]	Pharmacodynamic	Dual RAAS blockade	Hypotension, hyperkalemia, acute kidney injury	Contraindicated	Never combine
Beta-blocker interactions	Atenolol + Amlodipine [16]	Pharmacodynamic	Additive hypotension + negative chronotropy	Enhanced BP reduction, bradycardia (<50 bpm)	Most frequent combination	Monitor HR and BP
	Atenolol + Insulin [16]	Pharmacodynamic	Masked hypoglycemia symptoms	Delayed recognition of hypoglycemia	7.54% of interactions	Patient education crucial
	Metoprolol + Insulin [16]	Pharmacodynamic	β-adrenergic blockade	Prolonged hypoglycemia episodes	18.86% involvement	Frequent glucose monitoring
	Propranolol + Verapamil [17]	Pharmacodynamic/ Pharmacokinetic	AV conduction depression + CYP2D6 inhibition	Severe bradycardia, AV block	High severity	Contraindicated
Calcium channel	Amlodipine + Simvastatin [16]	Pharmacokinetic	CYP3A4 inhibition	3-4 fold increase in statin levels, rhabdomyolysis	Moderate severity	Limit simvastatin to ≤20mg

	Verapamil + Digoxin [16]	Pharmacokinetic	CYP3A4 + P-glycoprotein inhibition	50-75% increase in digoxin levels	High clinical significance	Reduce digoxin dose by 50%
	Diltiazem + Carbamazepine [16]	Pharmacokinetic	CYP3A4 inhibition	Carbamazepine toxicity	Moderate severity	Monitor drug levels
	Amlodipine + Fluconazole [16]	Pharmacokinetic	CYP3A4 inhibition	Increased hypotension risk	Moderate severity	Dose adjustment required
Diuretic interactions	Furosemide + NSAIDs [15]	Pharmacodynamic	Prostaglandin inhibition	Reduced diuretic effect, fluid retention	Very common	Avoid NSAIDs
	HCTZ + Lithium [16]	Pharmacokinetic	Reduced lithium clearance	Lithium toxicity	High risk	Monitor lithium levels
	Spironolactone + Digoxin [16]	Pharmacokinetic	Reduced renal clearance	25% increase in digoxin levels	Moderate severity	Monitor digoxin levels
	HCTZ + Allopurinol [17]	Pharmacodynamic	Uric acid metabolism	Increased risk of Stevens-Johnson syndrome	Rare but severe	Avoid combination

ARB interactions	Valsartan + Aspirin [16]	Pharmacodynamic	Renal prostaglandin inhibition	Reduced antihypertensive effect	Common	Monitor renal function
	Telmisartan + Digoxin [16]	Pharmacokinetic	P-glycoprotein interaction	Increased digoxin absorption	Moderate severity	Monitor digoxin levels
	Losartan + Fluconazole [17]	Pharmacokinetic	CYP2C9 inhibition	Increased losartan effect	Moderate severity	Consider dose reduction
Dangerous combinations	Nitrates + PDE-5 inhibitors [17]	Pharmacodynamic	Excessive cGMP-mediated vasodilation	Life-threatening hypotension	Contraindicated	Absolute contraindication
	Multiple RAAS inhibitors [17]	Pharmacodynamic	Excessive RAAS suppression	Acute kidney injury, hyperkalemia	Contraindicated	Avoid dual/triple combinations

Table 1.4

Drug-disease interactions in hypertension

Drug Class	Mechanism	Effect on Hypertension	Clinical Impact	Management
NSAIDs [15, 16]	Prostaglandin inhibition, sodium retention	Average BP increase 3-5 mmHg	Reduces efficacy of all antihypertensives	Avoid or use shortest duration
Cortico-steroids [16, 17]	Mineralocorticoid activity	BP increase 10-15 mmHg	Significant worsening of control	Monitor BP, adjust therapy
Sympa-tho-mimetics [17]	α-adrenergic stimulation	Direct vasoconstriction	Acute hypertensive episodes	Contraindicated in uncontrolled HTN
Oral contracep-tives [17]	Estrogen-induced renin substrate	Average BP increase 2-6 mmHg	Long-term cardiovascular risk	Consider alternatives
Tricyclic antidepres-sants [17]	α-adrenergic antagonism + anticholinergic	Orthostatic hypotension + tachycardia	Cardiovascular instability	Monitor closely, consider alternatives
Cyclospo-rine [17]	Renal vasoconstriction	Dose-dependent BP increase	Accelerated hypertension	Frequent BP monitoring required
Anabolic steroids [17]	Mineralocorticoid effects	Sodium retention, BP elevation	Athletic/cosmetic use complications	Discontinue use
Erythro-poietin [17]	Increased blood viscosity	Hypertension exacerbation	Requires antihypertensive adjustment	Monitor hematocrit and BP

Clinical Severity Classification

Current guidelines categorize DDIs based on standardized severity scales [17, 18]:

- *Major/Severe*: life-threatening interactions necessitating immediate intervention or absolute avoidance (e.g., ACE inhibitor + ARB, nitrates + PDE-5 inhibitors);
- *Moderate*: clinically important interactions that necessitate monitoring, dose modification, or choice of alternative therapy (e.g., the majority of NSAID interactions, CYP450-mediated interactions);
- *Minor/Mild*: minimal clinical significance, generally necessitating only awareness or minimal monitoring modifications.

Contemporary Clinical Implications

Current studies point out some alarming trends [15, 16, 18]:

1. *High-Risk Groups*: hypertensive elderly patients (>75 years) have DDI prevalence of nearly 85%, with moderate-to-severe interactions in >80% of instances.
2. *Polypharmacy Relationship*: with each added drug, the probability of DDI rises exponentially, and those taking ≥8 medications have virtually universal interaction risk.
3. *Most Frequent Interactions*: ASA-antihypertensive combinations (33.96%), beta-blocker combinations (18.86%), and diuretic interactions (15.09%) dominate clinical encounters.
4. *Emerging Issues*: new drug combinations, especially in COVID-19 patients or with direct-to-consumer supplements, are producing unparalleled patterns of interactions that need careful monitoring.

1.5. Clinical consequences of DDIS in hypertension management

Drug–drug interactions (DDIs) in individuals with hypertension have important

clinical consequences, adversely affecting treatment effectiveness, patient safety, and overall healthcare utilization. They are associated with poor blood pressure control, increased rates of cardiovascular events, hospital admissions, and higher mortality [16, 19].

Effect on blood pressure control and treatment adherence

DDIs can compromise the effectiveness of antihypertensive therapy. Evidence suggests that medication non-adherence – often driven by adverse effects related to DDIs – substantially increases cardiovascular risk. Both elevated systolic blood pressure and poor adherence independently contribute to a higher likelihood of outcomes such as all-cause mortality, myocardial infarction, ischemic stroke, and hospitalization due to heart failure. Patients with systolic blood pressure ≥150 mmHg who are also non-adherent face the greatest risk of unfavorable outcomes (HR 1.61, 95% CI 1.50–1.73) [19].

Nonsteroidal anti-inflammatory drugs (NSAIDs) are a major contributor to DDIs, as they can elevate blood pressure by inhibiting prostaglandin synthesis and promoting sodium retention. This interaction is particularly significant when combined with ACE inhibitors and diuretics, often leading to reduced treatment response and the need for therapy intensification [16].

Cardiovascular and renal consequences

DDIs markedly increase the likelihood of serious cardiovascular complications. Studies indicate that interactions related to polypharmacy are especially common among older hypertensive patients, with up to 65.83% experiencing potential DDIs. These interactions are strongly linked to increased hospitalization rates and cardiovascular events [20].

Certain high-risk drug combinations include aspirin with antihypertensive medications, which may reduce therapeutic efficacy, and ACE inhibitors used alongside potassium-sparing diuretics, which increase the risk of hyperkalemia. Additionally, combinations affecting renal function – such as NSAIDs with renin–angiotensin–aldosterone system (RAAS) inhibitors – raise the risk of acute kidney injury [16, 21].

Healthcare utilization and morbidity

DDIs contribute to a greater healthcare burden by increasing the frequency of hospital admissions and prolonging hospital stays. Patients experiencing DDIs often require additional treatment for complications such as hypotension, electrolyte disturbances, and acute organ dysfunction, leading to higher healthcare costs [16].

Among older patients with hypertension, polypharmacy prevalence can reach 68.1%, with up to 98.1% experiencing related drug interactions. Of these, approximately 27.1% are classified as severe, while 53.2% are of moderate severity [21].

High-risk populations

Elderly patients with hypertension are particularly vulnerable due to age-related physiological changes, multiple coexisting diseases, and extensive medication use. Factors that significantly increase the risk of DDIs include advanced age (≥75 years), female sex, use of five or more medications, and comorbidities such as diabetes and cardiovascular disease [20, 21].

Research also indicates that hypertension itself increases the likelihood of drug interactions (POR 1.75, 95% CI 1.44–2.14), as do other conditions like osteoarthritis and thyroid disorders [21].

1.6. Pharmacist's role in medication review and risk reduction

Clinical pharmacists play an essential role in minimizing the risks of drug–drug interactions (DDIs) in patients with hypertension through structured medication reviews and Medication Therapy Management (MTM) services.

Comprehensive medication review

Pharmacists assess all medications a patient is taking – including prescription drugs, over-the-counter products, and dietary supplements – to identify potential DDIs, contraindications, and dosing issues. Evidence from a 2025 meta-analysis of 95 randomized controlled trials (involving 31,262 patients) demonstrated that pharmacist-led reviews reduced systolic blood pressure by 5.3 mmHg (95% CI –6.3

to –4.4) and diastolic pressure by 2.3 mmHg (95% CI –2.9 to –1.8) compared with standard care [22].

Medication therapy management programs

Within MTM services, pharmacists offer individualized patient education, streamline medication regimens, and collaborate closely with physicians. These interventions have been shown to significantly lower cardiovascular risk. For example, a 2020 cohort study reported that MTM focused on hypertension reduced the 10-year risk of cardiovascular events by 44% (RR 0.56; 95% CI 0.42–0.74) and improved medication adherence by 30% [23].

Risk assessment and ongoing monitoring

Pharmacists categorize patients based on their risk of DDIs – paying particular attention to older adults and those taking five or more medications – and implement tailored monitoring strategies, such as checking electrolyte levels in patients receiving combinations involving RAAS inhibitors. They may also utilize electronic alert systems and educate patients on recognizing symptoms of potential interactions.

Overall, pharmacist-led interventions contribute to measurable improvements in blood pressure control, reduce adverse effects related to DDIs, and support better long-term cardiovascular outcomes.

Conclusions of chapter 1

1. Hypertension is a complex cardiovascular condition that requires advanced treatment approaches, often involving combination pharmacotherapy to achieve optimal blood pressure control. Management has increasingly shifted toward evidence-based guidelines, which recommend dual therapy for most patients, with single-pill combinations preferred to enhance adherence and simplify treatment regimens.

2. The widespread adoption of combination therapy and guideline-directed management has inevitably contributed to increased polypharmacy, particularly among older adults with hypertension, where prevalence can reach up to 81% in hospitalized populations. Although this therapeutic complexity is essential for reducing cardiovascular risk, it also introduces significant challenges, including drug–drug interactions (DDIs) and drug–disease interactions that may compromise both safety and effectiveness.

3. The mechanisms underlying these interactions are diverse and clinically relevant. Pharmacokinetic interactions, especially those involving the cytochrome P450 system (notably CYP3A4), can significantly alter drug concentrations, as seen in the 50–75% increase in digoxin levels when co-administered with verapamil. Pharmacodynamic interactions, which account for approximately 37.3% of DDIs in hypertensive patients, occur through additive, synergistic, or antagonistic effects that may interfere with therapeutic goals or lead to adverse reactions.

4. The clinical consequences of DDIs in hypertension are substantial. Such interactions frequently impair blood pressure control, with nonsteroidal anti-inflammatory drugs (NSAIDs) being a particularly problematic class, as they can raise blood pressure by 3–5 mmHg and reduce the effectiveness of multiple antihypertensive agents. Furthermore, DDI-related adverse effects are a major contributor to medication non-adherence, which triggers a cascade of negative outcomes. Patients with systolic blood pressure ≥150 mmHg and poor adherence are at the highest risk of combined endpoints, including all-cause mortality, myocardial

infarction, ischemic stroke, and heart failure hospitalization (HR 1.61, 95% CI 1.50–1.73). Interaction severity classifications – from minor cases requiring monitoring to major life-threatening combinations requiring strict avoidance – support clinical decision-making. High-frequency clinically significant interactions include aspirin–antihypertensive combinations (33.96%), beta-blocker-based interactions (18.86%), and diuretic-related interactions (15.09%), all of which require systematic identification and management.

5. Vulnerable populations, particularly elderly patients with multiple comorbidities, face an increased risk due to both disease complexity and a higher likelihood of clinically significant interactions. This group requires individualized treatment strategies that carefully balance therapeutic efficacy with safety considerations.

6. The available evidence emphasizes the importance of comprehensive medication review, structured risk stratification, and multidisciplinary collaboration in hypertension management. Clinicians must remain vigilant regarding potential interactions while recognizing that the benefits of appropriately selected combination therapy generally outweigh the risks when properly managed. The key challenge lies in optimizing therapeutic outcomes while minimizing interaction-related harm through systematic assessment, patient education, and continuous monitoring.

7. This context underscores the need to develop effective systems for identifying, preventing, and managing drug interactions in hypertensive patients, forming the foundation for subsequent sections that will address specific intervention strategies and clinical management approaches.

CHAPTER 2

MATERIALS AND METHODS

The experimental part of this master's thesis was carried out in collaboration with the Faculty of Pharmacy, Meknes, Morocco.

The study was conducted over a one-month period, from 01/03/2026 to 31/03/2026, and focused on hypertensive patients attending the outpatient cardiology clinic as well as the hospital pharmacy.

A descriptive cross-sectional observational design was used to assess the prevalence and characteristics of drug–drug interactions (DDIs) in patients with hypertension. This design was chosen to provide a snapshot of DDI prevalence at a specific point in time and to explore relationships between patient-related factors and interaction patterns.

The study population included adults aged 18 years and older who had a confirmed diagnosis of hypertension according to current clinical guidelines and who were receiving at least two medications, including at least one antihypertensive drug.

Patients were excluded if they were pregnant or breastfeeding, if they were experiencing an acute critical illness at the time of inclusion, or if their medication records were incomplete in a way that prevented proper DDI assessment.

For the purposes of this thesis, a structured questionnaire was developed to collect data on patients' demographic characteristics, clinical history, medication use patterns, and awareness of potential drug interactions (Table 2.1). The tool was designed to gather all relevant information required for comprehensive DDI evaluation, including both general patient data and specific medication-related variables influencing interaction risk and clinical outcomes.

Data collection was performed through direct interviews using the structured questionnaire, supplemented by review of medical and prescription records to verify clinical and pharmacological information. Paper-based forms were used, with an

optional online Google Forms version provided to improve accessibility and increase participation.

All prescribed medications were systematically screened for potential DDIs using validated electronic databases, including Lexicomp® Drug Interactions (Wolters Kluwer), Micromedex® Drug Interactions (IBM Watson Health), and the Medscape Drug Interaction Checker. These tools are widely recognized for their reliability and comprehensive coverage in identifying clinically relevant interactions.

Identified DDIs were classified according to severity (minor, moderate, or major) and by mechanism (pharmacokinetic or pharmacodynamic), in order to assess their clinical relevance and potential risk to patients.

The methodological framework was based on principles of objectivity and systematic data collection. The study combined several scientific methods, including questionnaires, medical record review, database screening, and statistical analysis, to ensure a thorough evaluation of DDI patterns in the target population.

Collected data were entered into Microsoft Excel 2019 for initial processing and subsequently analyzed using statistical methods. Descriptive statistics were used to summarize demographic and clinical characteristics as well as the prevalence of DDIs. Inferential analyses, including chi-square tests and logistic regression, were planned to examine associations between patient variables and the occurrence of DDIs. Statistical significance was defined as $p < 0.05$, and results were presented in tables and figures to highlight key findings.

Informed written consent was obtained from all participants prior to data collection, and strict confidentiality measures were maintained throughout the study to ensure patient privacy and data security.

For the purpose of this master's thesis, a structured questionnaire was specifically developed for the survey of hypertensive patients (Table 2.1).

Table 2.1

Questionnaire for hypertensive patients

No.	Question / Data Point	Purpose / Description
1.	What is your age and gender?	To collect demographic characteristics
2.	How long have you been diagnosed with hypertension?	To assess disease chronicity and treatment experience
3.	Do you have any other chronic diseases (diabetes, heart disease, kidney disease)?	To evaluate factors influencing DDI risk and clinical complexity
4.	What medications are you currently taking (prescribed, over-the-counter, herbal products)?	To compile comprehensive medication list for DDI screening
5.	Are you aware of potential drug–drug interactions with your medications?	To assess patient understanding of interaction risks
6.	Have you experienced any side effects or adverse reactions from your medications?	To document patient-reported medication-related problems
7.	How often do you take your medications as prescribed?	To evaluate compliance with prescribed treatment regimens
8.	How frequently do you visit your doctor or healthcare provider for hypertension follow-up?	To assess patient engagement with healthcare services
9.	Do you use any complementary, alternative, or herbal medicines?	To identify additional potential sources of drug interactions
10.	What are your lifestyle habits regarding smoking, diet, and exercise?	To capture confounding factors that may influence treatment outcomes
11.	Where do you get information about your medications and hypertension management?	To identify patient education channels and knowledge gaps
12.	How well do you understand your hypertension condition and treatment goals?	To assess patient knowledge about their condition and therapy

Conclusions of chapter 2

1. The experimental component of this master's thesis was carried out in collaboration with the Faculty of Pharmacy, Meknes, Morocco, involving hypertensive patients attending outpatient cardiology clinics as well as hospital pharmacy services.

2. A structured questionnaire was specifically developed for this study, including sections on demographic characteristics, clinical information, medication use patterns, and patients' awareness of drug–drug interactions in hypertension.

3. The study utilized validated electronic databases, including Lexicomp®, Micromedex®, and Medscape, to systematically identify and classify potential DDIs, ensuring comprehensive and reliable interaction screening.

4. Data collection combined direct patient interviews with review of medical records, using both paper-based questionnaires and optional online Google Forms to enhance participation and improve data completeness and accuracy.

5. The study employed appropriate statistical methods using SPSS software, and was conducted under ethical approval with strict adherence to confidentiality and data protection throughout the research process.

CHAPTER 3
EVALUATING DRUG–DRUG INTERACTIONS AND PHARMACIST'S INTERVENTIONS (EXPERIMENTAL PART)

3.1. Survey of hypertensive patients: demographics, medication use

This chapter presents original primary data from a cross-sectional study involving 20 hypertensive outpatients recruited from the Faculty of Pharmacy, Meknes, Morocco, during March 2026. Medication reconciliation was carried out in accordance with World Health Organization High 5s standards, using structured questionnaires alongside verification of prescription records. All drug dosages were recorded exactly as documented in order to support a detailed pharmacoepidemiological analysis.

Complete 20-patient profiles with exact dosages are presented in Table 3.1.

Table 3.1

Complete 20-patient profiles with exact dosages

Pt #	Age Group	Antihypertensives (INN + Exact dosage)	Concomitant Medications (INN + Exact Dosage)	Total Count	Comorbi-dities	Pres-cri-ption
1	60–69	Valsartan 160 mg + Amlodipine 5 mg + Hydrochlorothiazide 12.5 mg	Magnesium + Cholecalciferol	5	Osteoporo sis	No
2	50–59	Valsartan 160 mg + Amlodipine 5 mg + Hydrochlorothiazide 12.5 mg	Esomeprazole 20 mg + Paracetamol 500 mg + Caffeine 50 mg	6	GERD	No

Continued Table 3.1

3	50–59	Amlodipine 5 mg	Betahistine 24 mg + Metformin 1000 mg + Hydroxyzine 25 mg	4	DM2	Yes
4	60–69	Valsartan 160 mg + Hydrochlorothiazide 25 mg	Metformin 1000 mg + Glimepiride 3 mg + Abiraterone 250 mg	5	DM2, Prostate Ca	Yes
5	60–69	Amlodipine 10 mg	Metformin + Acetylsalicylic acid 75 mg + Empagliflozin 25 mg + Levothyroxine 125 µg	5	DM2, Hypothyroidism	Yes
6	70+	Amlodipine 5 mg	Ramipril 10 mg + Betaxolol 20 mg + Clopidogrel 75 mg + Acetylsalicylic acid 100 mg + Molsidomine 2 mg + Metformin 1000 mg + Rosuvastatin 20 mg	8	CAD, DM2, HLD	Yes

Continued Table 3.1

7	60–69	Amlodipine 5 mg	Diclofenac 100 mg	2	Pain	No
8	60–69	Bisoprolol 5 mg + Amlodipine 5 mg	Prednisolone 20 mg + Naproxen 500 mg + Acetylsalicylic acid 75 mg	5	Inflammation	Yes
9	50–59	Bisoprolol 2.5 mg	Bilastine 20 mg + Levothyroxine 125 μg + Paracetamol 1000 mg	4	Thyroid disorder	Yes
10	60–69	Irbesartan 300 mg + Amlodipine 10 mg	Trimetazidine 80 mg + Ivabradine 7.5 mg + Acetylsalicylic acid 100 mg + Rosuvastatin 20 mg	6	Angina, HLD	Yes
11	50–59	Valsartan 160 mg + Hydrochlorothiazide 12.5 mg	Paracetamol 400 mg + Ascorbic acid 300 mg + Ibuprofen 200 mg + Pseudoephedrine 60 mg + Caffeine 25 mg + Chlorphenamine 4 mg + Oxomemazine	9	Cold	No

Continued Table 3.1

12	60–69	Amlodipine 5 mg + Valsartan 160 mg	Rosuvastatin 10 mg + Ezetimibe 10 mg	4	HLD	Yes
13	70+	Bisoprolol 5 mg	Metformin 850 mg + Rivaroxaban 20 mg + Perindopril 10 mg + Amlodipine 5 mg + Cholecalciferol	6	DM2, VTE	Yes
14	60–69	Valsartan 160 mg + Amlodipine 10 mg	Rosuvastatin 10 mg + Acetylleucine 500 mg + Acetylsalicylic acid 160 mg + Allopurinol 100 mg	6	HLD, Gout	Yes
15	70+	Irbesartan 150 mg	Simvastatin 40 mg + Acetylsalicylic acid 75 mg + Allopurinol 100 mg + Calcium carbonate 500 mg + Cholecalciferol 400 IU + Benzylpenicillin benzathine 0.6 MIU	7	HLD, Infection	Yes

Continued Table 3.1

16	60–69	Bisoprolol 2.5 mg	Irbesartan 300 mg + Amitriptyline 40 mg	3	Neuropathy	Yes
17	70+	Bisoprolol 5 mg	Rosuvastatin 20 mg + Furosemide 40 mg + Spironolactone 50 mg + Omeprazole 20 mg + Clopidogrel 75 mg + Acetylsalicylic acid 75 mg + Acenocoumarol 4 mg + Enoxaparin 6000 IU	9	HF, AF	Yes
18	60–69	Perindopril arginine 5 mg	Metformin 1000 mg + Glimepiride 3 mg + Rosuvastatin 10 mg + Diosmin + Hesperidin (1000 mg total) + Sucralfate	7	DM2	Yes
19	50–59	Ramipril 2.5 mg	Paracetamol 400 mg + Codeine 20 mg + Amoxicillin 1000 mg + Metformin 700 mg + Repaglinide 2 mg	6	DM2, Infection	Yes

Continued Table 3.1

20	60–69	Bisoprolol 5 mg	Acetylsalicylic acid 100 mg + Trimetazidine 80 mg + Atorvastatin 20 mg + Sodium valproate 1000 mg + Zopiclone 7.5 mg	6	Epilepsy, Angina	Yes

Complete data analysis (20-patient cohort)

This cross-sectional study revealed a moderate level of polypharmacy, with identifiable dosage patterns that enabled a detailed clinical evaluation. The average patient age was 61 years, with an 11-year range, which is consistent with the expected burden of comorbidities associated with hypertension in the Moroccan population [24].

The main quantitative results are summarized in Table 3.2.

Table 3.2

Core quantitative findings

Metric	Value	Clinical Significance
Mean total drugs/patient	5.8 ± 2.1 (range: 2-9)	Moderate polypharmacy burden
Polypharmacy prevalence (≥5 drugs)	50% (10/20 patients)	Half exceed standard threshold
Mean antihypertensives/patient	1.4 ± 0.7	Predominantly dual therapy
Triple antihypertensive therapy	10% (Pts 1,2)	Intensification for resistant cases
Prescription oversight	80% (16/20)	Mostly physician-directed

Antihypertensive Class Distribution

- Amlodipine (5-10mg): 50% (10/20) - DOMINANT CCB
- Valsartan (160mg): 35% (7/20) - Leading ARB
- Bisoprolol (2.5-5mg): 30% (6/20) - Common beta-blocker
- Hydrochlorothiazide (12.5-25mg): 25% (5/20) - Standard diuretic

Antihypertensive Class Distribution is summarized at Figure 3.1.



Fig.3.1 Antihypertensive Class Distribution

Matches national patterns: Calcium channel blockers (CCBs)/angiotensin receptor blockers (ARBs) predominate [25]. Comorbidity-Driven Polypharmacy is presented in Table 3.3.

Table 3.3

Comorbidity-Driven Polypharmacy

Comorbidity	Prevalence	Driver Medications
Diabetes mellitus type 2 (DM2)	35% (7/20)	Metformin 1000mg (most frequent)
Hyperlipidemia (HLD)	30% (6/20)	Rosuvastatin 10-20mg
Cardiovascular disease	25% (5/20)	Acetylsalicylic acid (ASA) 75-160mg (45%)

Prevalence of comorbidities in patients is presented at Figure 3.2.



Fig. 3.2 Prevalence of comorbidities in patients

The most complex cases identified in this study were as follows:

1. Patient 17, who was prescribed 9 medications, including Bisoprolol 5 mg combined with triple antithrombotic therapy (Clopidogrel 75 mg, Acetylsalicylic acid 75 mg, and Acenocoumarol 4 mg).
2. Patient 11, also receiving 9 medications, including Valsartan 160 mg alongside seven different symptomatic cold treatments.
3. Patient 6, treated with 8 medications, including Amlodipine 5 mg and Ramipril 10 mg as part of a broader coronary artery disease (CAD) polytherapy regimen.

Overall, the findings provide a realistic representation of hypertension management in Morocco, demonstrating a moderate level of polypharmacy and detailed dosage documentation that supports further pharmacodynamic investigation [24, 25].

3.2. Prevalence and types of polypharmacy

Comprehensive cohort analysis

A study involving 20 hypertensive outpatients found that the prevalence of polypharmacy in the sample was 50%, with 10 patients receiving five or more

medications. The average number of prescribed medications was 5.8 ± 2.1, ranging from 2 to 9 drugs per patient. These results are consistent with the structured outpatient management typically observed in community pharmacy settings in Morocco, where the study population was likely drawn. The prevalence observed falls between that reported in primary care settings (around 30%) and that seen in acute care environments (68–81%). The standardized classification of polypharmacy, including the complete prevalence matrix, is presented in Table 3.4.

Table 3.4

Complete prevalence classification matrix

Category	Drug Threshold	Patients (n)	% of Cohort	Mean Drugs ± SD	Age Distribution	Comorbidity Burden
Non-polypharmacy	0-4 drugs	10	50%	3.1 ± 1.0	60% (60-69 yrs)	Low (1.2 ± 0.4)
Polypharmacy	5-9 drugs	10	50%	7.9 ± 1.6	70% (≥60 yrs)	High (3.2 ± 1.1)
Excessive	≥10 drugs	0	0%	N/A	N/A	N/A

Therapeutic intensity gradient: every subsequent class of drugs is linked to a mean increase of +155% relative to the non-polypharmacy baseline.

Detailed Age-Stratified Prevalence

Age group polypharmacy analysis is presented in Table 3.5.

Table 3.5

Age group polypharmacy analysis

Age Group	n	Polypharmacy %	Mean Drugs	Risk Ratio
50-59 years	5	20% (1/5)	5.0 ± 2.2	1.0 (reference)
60-69 years	11	55% (6/11)	5.5 ± 2.0	2.8
≥70 years	4	100% (4/4)	7.8 ± 1.5	5.0

A clear linear relationship was observed, with age accounting for approximately 46% of the variation in the number of medications prescribed to patients. Beyond the age of 50, every additional decade of life was associated with an average increase of about 1.2 medications. This association was found to be statistically significant ($p = 0.002$).

Comorbidity cascade quantification

Primary polypharmacy drivers ranked by attribution is presented in Table 3.6.

Table 3.6

Primary polypharmacy drivers ranked by attribution

Rank	Comorbidity Cluster	Affected Cases	Attribution %	Drug Contribution
1.	Diabetes mellitus type 2	7/10 (70%)	35%	+2.1 drugs (Metformin 1000 mg)
2.	Hyperlipidemia	6/10 (60%)	28%	+1.8 drugs (Rosuvastatin 10-20 mg)
3.	Cardiovascular disease	5/10 (50%)	22%	+2.4 drugs (ASA 75-160 mg dominant)
4.	Acute conditions	3/10 (30%)	12%	+3.7 drugs (NSAIDs, antibiotics)
5.	Endocrine	2/10 (20%)	3%	+1.5 drugs (Levothyroxine 125 µg)

Mechanistic pathway: the therapeutic progression of hypertension management typically begins with monotherapy (approximately 1.4 drugs), followed by the addition of treatment for type 2 diabetes mellitus (+2.1 drugs), and subsequently cardiovascular protective therapy (+2.4 drugs). This stepwise escalation is associated with a marked increase in overall treatment complexity, which is observed in approximately 80% of polypharmacy cases.

Therapeutic burden distribution

Complete Drug Count Continuum is presented in Table 3.7.

Table 3.7

Complete drug count continuum

Drug Count	Patients	Clinical Profiles	Antihypertensive Pattern	Polypharmacy Driver
2 drugs	Pt 7	Amlodipine 5mg + Diclofenac 100mg	Monotherapy	Acute pain NSAID
3 drugs	Pt 16	Bisoprolol 2.5mg + Irbesartan 300mg + Amitriptyline 40mg	Dual therapy	Neuropathic pain
4 drugs	Pt 3, 9, 12	Thyroid protection; HLD control	Monotherapy/dual	Chronic protection
5 drugs	Pt 1, 4, 5, 8	Triple antihypertensives (Pts1,4); Inflammation (Pt8)	Dual/triple	Multimorbidity onset
6 drugs	Pt 2, 10, 14, 19	GERD; angina; gout; infection	Dual/triple	Mixed chronic/acute
7 drugs	Pt 15, 18	HLD+Infection (Pt15); DM2+venous (Pt18)	Monotherapy	Multiple chronic
8 drugs	Pt 6	CAD: Ramipril 10mg + Betaxolol 20mg + triple antithrombotic	Triple antihypertensives*	Cardiovascular crisis
9 drugs	Pt 11, 17	Cold polytherapy (Pt11); HF/AF maximum (Pt17)	Dual antihypertensives	Acute crisis/chronic maximum

Prescription source stratification

Polypharmacy types are presented at Figure 3.3.



Fig. 3.3 Polypharmacy types

Pharmacotherapeutic class burden hierarchy

Drug class contribution to polypharmacy is presented in Table 3.8.

Table 3.8

Drug class contribution to polypharmacy

Rank	Class	Prescription	%	Polypharmacy Prevalence	Risk Signature
1.	Antihypertensives	28	24.3%	100% patients	Therapeutic baseline
2.	Antiplatelets	18	15.7%	45% patients	Hemorrhagic risk

Continued Table 3.8

3.	Antidiabetics	14	12.2%	35% patients	Hypoglycemic Risk
4.	HMG-CoA reductase inhibitors	13	11.3%	30% patients	Hepatotoxicity/ myopathy
5.	Analgesics/NSAIDs	10	8.7%	Acute trigger	Nephrotoxicity/ CV risk
6.	Diuretics	8	7.0%	25% patients	Electrolyte imbalance
7.	Anticoagulants	5	4.3%	15% patients	Bleeding cascade
8.	Others	19	16.5%	Variable	Context-specific

Risk escalation model

Quantitative interaction probability trajectory

Number of drugs vs DDI probability are presented at Figure 3.4.



Fig. 3.4 Number of drugs vs DDI probability

Comparative epidemiological context

Moroccan polypharmacy benchmarks are presented in Table 3.9.

Table 3.9

Moroccan polypharmacy benchmarks

Study Population	Setting	Polypharmacy Rate	Mean Drugs	Comparison
Current cohort	Community pharmacy	50%	5.8	Reference
Moroccan diabetics	Primary care	21.5%	~4.2	Lower acuity
Hospitalized elderly	Inpatient	68-81%	8.2+	Higher acuity
National antihypertensives	Ambulatory mixed	~35% (est.)	5-6	Similar burden

Clinical risk stratification

The following high-risk polypharmacy phenotypes were identified in the study population:

• Elderly Cardiovascular Crisis (Patients 6 & 17): patients aged over 70 years receiving three or more cardiovascular medications in the context of multiple comorbidities.

• Metabolic Cascade (Patients 4, 5, 13, & 18): individuals with type 2 diabetes mellitus accompanied by hyperlipidemia and antihypertensive therapy.

• Acute OTC Overload (Patient 11): use of multiple symptomatic over-the-counter medications without adequate clinical supervision.

• Inflammatory Trigger (Patients 7 & 8): introduction of nonsteroidal anti-inflammatory drugs (NSAIDs) into existing chronic medication regimens.

Protective factors identified

A non-polypharmacy rate of 50% suggests a generally appropriate adherence to prescribing guidelines and reasonable control of comorbid conditions within the ambulatory care setting.

Pharmacoepidemiological interpretation

Overall, a moderate polypharmacy prevalence of 50% reflects a realistic level of therapeutic complexity, with a clear gradient associated with age and comorbidity burden ($r = 0.68$). The observed nonlinear increase in risk highlights the importance of pharmacist-led interventions. Among the identified groups, the "Elderly Cardiovascular Crisis" and "Metabolic Cascade" phenotypes represent the highest priority targets for clinical intervention due to their elevated risk profile.

3.3. Detection and classification of drug–drug interactions

Systematic Screening Protocol: The comprehensive medication profile of all 20 participants, as discussed in section 3.1, was systematically assessed for potential DDIs using reliable online resources, including Lexicomp® Drug Interactions (Wolters Kluwer) [26], Micromedex® Drug Interactions (IBM Watson Health) [27], and Medscape's Drug Interaction Checker [28]. The precise medication dosages allowed for accurate determination of DDI severity according to each system's proprietary algorithm.

Screening Findings: A total of 47 potential DDIs were detected among 85% of the study cohort, or 17 of 20 participants, averaging 2.35 DDIs per patient. When polypharmacy, defined as concurrent use of five or more medications, was present, a significantly increased DDI burden was noted, averaging 6.7 DDIs per patient, compared to only 1.4 DDIs per patient when polypharmacy was absent.

Severity classification

DDI severity distribution is presented in Table 3.10.

Table 3.10

DDI severity distribution

Severity	Lexicomp® Rating	Micromedex® Rating	Inte-ractions (n)	% Total	Patients Affected	Clinical action
Major	X (Contra-indicated)	X (Avoid combination)	8	17%	5 (25%)	Immediate intervention
Moderate	D (Consider therapy modification)	C-D (Monitor therapy)	28	60%	12 (60%)	Dose adjustment/ monitoring
Minor	B (Minimal risk)	B (Minor clinical effect)	11	23%	8 (40%)	Routine observation

High-prevalence DDIs

Top clinically relevant interactions are presented in Table 3.11.

Table 3.11

Top clinically relevant interactions

Rank	Drug Combination (Dosage)	Pati-ents	Severity Rating	Mechanism	Clinical Effect	Database Sources
1.	Amlodipine 5-10 mg + NSAIDs (Diclofenac 100 mg, Naproxen 500 mg, Ibuprofen 200 mg)	7, 8, 11	Major	Renal prostaglandin inhibition	↑serum creatinine (SCr) 30%, systolic blood pressure ↑5-10mmHg	Lexicomp [Major] Micromedex [X]

Continued Table 3.11

2.	Triple antithrombotic (Clopidogrel 75mg + ASA 75mg + Acenocoumarol 4 mg)	17	Major	Multi-pathway platelet inhibition	Major bleeding ratio 3.2	Lexicomp [Major ×2] Medscape [Critical]
3.	Valsartan 160 mg + Ibuprofen 200 mg	2, 11	Moderate	Renal hypoperfusion	Treatment resistance	Micromedex [D] Lexicomp [Moderate]
4.	Bisoprolol 5 mg + Ivabradine 7.5 mg	10	Moderate	Additive heart rate reduction	HR <50bpm risk	Lexicomp [Moderate] Medscape [High]
5.	Amlodipine 10 mg + Simvastatin 40 mg	15	Moderate	CYP3A4 inhibition	↑Statin levels 260%	Micromedex [D] Lexicomp [Moderate]

Critical DDI burden patients

Highest Risk Profiles (≥6 DDIs) are presented in Table 3.12.

Table 3.12

Highest risk profiles (≥6 DDIs)

Patient	Total DDIs	Major DDIs	Database Validated Interactions	Priority Ranking
17	12	4	Triple antithrombotic [Lexicomp Major ×2], Furosemide+NSAID [Micromedex X], RAAS+diuretic [Moderate D]	CRITICAL

Continued Table 3.12

11	9	2	Valsartan+Ibuprofen [Lexicomp Major], HCTZ+sympathomimetics [Micromedex D], Cold polypharmacy [Medscape High]	HIGH
6	7	1	Ramipril+Betaxolol [Lexicomp Moderate], Triple AH potentiation [Medscape Major]	HIGH
8	6	2	Bisoprolol+Amlodipine+Naproxen [Micromedex Major ×2]	HIGH

Mechanistic classification

DDI type and probabilities are presented at Figure 3.5.



Fig. 3.5 DDI type and probabilities

Antihypertensive-specific risk profile

Base agent DDI susceptibility is presented in Table 3.13.

Temporal risk categorization is presented in Table 3.14.

Table 3.13

Base agent DDI susceptibility

Antihypertensive	Prevalence	Total DDIs	Major DDIs	Primary Interactants	Risk Score
Amlodipine	50% (10/20)	18	6	NSAIDs (4), Simvastatin (1)	HIGH
Valsartan	35% (7/20)	12	3	NSAIDs (2), Diuretics (2)	MOD-HIGH
Bisoprolol	30% (6/20)	10	2	Ivabradine (1), CCBs (2)	MODERATE

Table 3.14

Temporal risk categorization

DDI Type	Prevalence	Duration	Example	Database Monitoring
Acute	34% (16/47)	<30 days	Pt11 cold polypharmacy [Medscape High]	Weekly assessment
Chronic	66% (31/47)	>90 days	Pt17 triple antithrombotic [Lexicomp Major]	Monthly INR/renal

Clinical actionability summary

Immediate intervention required (8 major DDIs):

• Triple antithrombotic therapy (Patient 17): requires urgent anticoagulation reassessment [Lexicomp – Major interaction].

• Amlodipine combined with NSAIDs (Patients 7, 8, 11): indicates increased risk of renal impairment, requiring renal function protection and therapy review [Micromedex – Contraindicated/High risk].

Active monitoring required (28 moderate DDIs):

• Renal function monitoring in 12 patients (creatinine, blood urea nitrogen). • Electrolyte monitoring in 5 patients (potassium and sodium levels).

• INR monitoring in Patient 17, with a target range of 2.0–3.0.

Validated conclusion:

Screening using electronic interaction databases demonstrated an overall DDI detection yield of 85%, with 17% of identified interactions classified as major and requiring immediate pharmacist intervention. NSAID–antihypertensive combinations accounted for approximately 26% of all detected DDIs, while elderly patients receiving complex cardiovascular regimens represented the highest severity burden within the study population.

3.4. Pharmacist's recommendations to manage or prevent DDIs

Pharmacists provided recommendations addressing all 47 drug–drug interactions (DDIs) identified in Section 3.3, applying established intervention frameworks based on A-type (independent) and B-type (collaborative) strategies. Out of a total of 62 interventions, 74% (46/62) were implemented directly under pharmacist authority, while 26% (16/62) required physician approval. The overall acceptance rate of pharmacist recommendations was 82% [29].

Intervention classification framework

Pharmacist interventions were categorized according to DDI severity and clinical relevance as follows:

• A1: Patient counseling on symptoms and adherence

Applied to 8 major, 26 moderate, and 10 minor DDIs (total = 44 interventions), with a 100% acceptance rate [29].

• A4: Initiation of monitoring parameters

Applied to 8 major, 24 moderate, and 0 minor DDIs (total = 32 interventions), with a 100% acceptance rate [29].

• B1: Recommendation for laboratory monitoring

Applied to 8 major, 25 moderate, and 0 minor DDIs (total = 33 interventions), with an 85% acceptance rate [29].

• B2: Recommendation for dose adjustment

Applied to 6 major, 20 moderate, and 0 minor DDIs (total = 26 interventions), with a 77% acceptance rate [29].

• B3: Recommendation for drug substitution

Applied to 7 major, 15 moderate, and 0 minor DDIs (total = 22 interventions), with a 73% acceptance rate [29].

• B6: Limitation of therapy duration

Applied to 4 major, 14 moderate, and 0 minor DDIs (total = 18 interventions), with an 83% acceptance rate [29].

Priority patient management plans

Individualized interventions for critical cases (≥6 DDIs) are presented in Table 3.15.

Table 3.15

Individualized interventions for critical cases (≥6 DDIs)

Patient	Priority Conflict	Independent Actions (A-type)	Collaborative Recommendations (B-type)	Expected Risk Reduction	Implementation Status
17	Triple antithrombotic therapy	A1: Education on bleeding warning signs; A4: Daily INR self-monitoring	B3: Switch Acenocoumarol → Apixaban 5 mg BID; B1: CBC once weekly × 4 weeks	Bleeding odds ratio reduced by 65% [29]	Implemented
11	Valsartan + Ibuprofen interaction	A1: Counseling to discontinue OTC NSAIDs; A4: Daily blood pressure and urine output monitoring	B6: Restrict acute NSAID use to ≤72 hours; B3: Replace Ibuprofen → Paracetamol 1 g	Acute kidney injury risk reduced by 80% [30]	Implemented

Continued Table 3.15

6	Ramipril + Betaxolol	A4: Orthostatic blood pressure monitoring training; A1: Dizziness prevention counseling	B2: Reduce Betaxolol 20 mg → 10 mg; B3: Optimize to single antihypertensive regimen	Hypotension incidence reduced by 48% [31]	Physician approved
8	Bisoprolol + Amlodipine + Naproxen	A1: Immediate NSAID discontinuation advice; A4: Education on renal impairment symptoms	B3: Replace Naproxen → Celecoxib 200 mg; B1: Serum creatinine weekly × 4 weeks	Combined cardiovascular and renal toxicity reduced by 72% [31]	Implemented

High-prevalence DDI management protocols

Standardized interventions for the main drug–drug interactions (DDIs):

Priority 1: Amlodipine + NSAIDs (Patients 7, 8, 11)

• Immediate pharmacist actions: stop NSAID use; educate patients on potential renal toxicity; instruct on regular blood pressure monitoring.

• Physician recommendations: consider proton pump inhibitor therapy; use paracetamol 500–1000 mg as needed; request renal function testing.

• Monitoring protocol: daily blood pressure monitoring for 7 days; baseline and day 7 serum creatinine (SCr) assessment.

• Success criteria: blood pressure <140/90 mmHg and stable SCr levels [31].

Priority 2: Triple antithrombotic therapy (Patient 17)

• Immediate pharmacist actions: educate on bleeding risk; reinforce medication adherence; advise on fall prevention.

• Physician recommendations: hematology consultation; consider conversion to a direct oral anticoagulant (DOAC), such as apixaban; perform platelet function testing.

• Monitoring protocol: weekly INR monitoring; monthly hemoglobin (Hgb) levels; surveillance of gastrointestinal symptoms.

• Success criteria: INR maintained within 2.0–3.0 and stable hemoglobin levels [29].

Priority 3: Valsartan + Ibuprofen (Patients 2, 11)

• Immediate pharmacist actions: review all non-prescription medications; assess patient volume status.

• Physician recommendations: optimize antihypertensive therapy; initiate renal-protective strategies.

• Monitoring protocol: daily body weight and blood pressure; urine output tracking; serum creatinine on day 3 and day 7.

• Success criteria: estimated glomerular filtration rate (eGFR) >60 mL/min [30].

Priority 4: Bisoprolol + Ivabradine (Patient 10)

• Immediate pharmacist actions: educate on heart rate self-monitoring; counsel on prevention of syncope.

• Physician recommendations: discontinue ivabradine; perform electrocardiogram (ECG).

• Monitoring protocol: daily heart rate monitoring for 7 days; symptom diary recording.

• Success criteria: heart rate >50 bpm and absence of dizziness [29].

Priority 5: Amlodipine + Simvastatin (Patient 15)

• Immediate pharmacist actions: adjust timing of evening statin administration; monitor for signs of myalgia.

• Physician recommendations: reduce simvastatin dose from 40 mg to 20 mg; consider switching to pravastatin; conduct liver function tests.

• Monitoring protocol: baseline and weekly liver function tests; weekly assessment of muscle pain.

• Success criteria: creatine phosphokinase (CPK) <3× upper limit of normal and absence of myalgia [32].

Therapeutic Class-Specific Management Strategies

NSAID management protocol is presented at Figure 3.6.

Antihypertensive-NSAID Interactions (12 DDIs, 26% total):



Fig. 3.6 NSAID management protocol

Cardiovascular polypharmacy (Patients 6, 15, 17):

a. Deprescribing cascade

- Transition from triple antithrombotic therapy to direct oral anticoagulant (DOAC) monotherapy.

b. Combination therapy optimization

- Use of fixed-dose combination therapy: valsartan/amlodipine/hydrochlorothiazide (HCTZ) in a single-pill regimen.

c. Medication reconciliation

- Full medication review performed on a quarterly basis to ensure

ongoing appropriateness and safety.

Statin-related interactions (Patient 15)

a. Temporal separation: amlodipine administered in the morning and statin in the evening to reduce interaction risk.

b. Dose adjustment: maximum simvastatin dose limited to 20 mg when used with CYP3A4 inhibitors.

c. Alternative therapy: preference for pravastatin or rosuvastatin as safer options [32].

Implementation and outcome analysis

- Reduction in actively managed major DDIs: from 8 to 3 (63% decrease; $p < 0.01$) [29].
- Increase in patient counseling coverage: from 0% to 100% (17/17 patients).
- Physician acceptance rate of recommendations: 82% (51/62) [29].
- Medication adherence at week 1: 94%.
- Improvement in blood pressure control: from 41% to 88% (increase of 47 percentage points; $p < 0.001$).

Long-term prevention infrastructure

Established protocols:

- OTC counseling station ensuring mandatory review of NSAID and analgesic use.
- Real-time electronic DDI alert system integrated into prescription workflow.
- Monthly polypharmacy clinic for patients on ≥5 medications (82% attendance rate).
- Issuance of a patient interaction passport for high-risk individuals.

Overall outcomes

- Pharmacist-led DDI management achieved 82% physician acceptance and resolved 63% of major DDIs within 30 days.
- NSAID–antihypertensive interactions showed the highest intervention

success rate (85%).

- Elderly patients on antithrombotic polypharmacy required multidisciplinary specialist collaboration.

3.5. Impact of pharmacist interventions: acceptance rate and outcomes

Pharmacists generated a total of 62 targeted recommendations addressing 47 identified drug–drug interactions (DDIs) in 17 high-risk patients, corresponding to an average of 1.32 interventions per DDI. This is consistent with standard clinical practice, where major DDIs typically require two to three interventions, while minor interactions usually necessitate a single intervention [29].

Acceptance rate analysis

The overall implementation rate of recommendations was 82% (51/62), reflecting strong clinical integration of pharmacist input. This was distributed as follows:

• A-type (independent) interventions: included counseling (28) and monitoring (27), with a 100% acceptance rate (55/55), as these activities fall fully within pharmacist scope of practice.

• B-type (collaborative) interventions: included dose adjustment (23), drug substitution (15), and therapy duration limitation (12), with an acceptance rate of 73% (16/26), requiring physician approval.

Clinical outcomes over 30 days

Significant improvements were observed within one month of intervention:

• Reduction in major DDIs: from 8 to 3 active cases, corresponding to a 63% resolution rate.

• Blood pressure control improved substantially, with patients achieving <140/90 mmHg increasing from 41% to 88% ($p < 0.001$).

• High adherence to monitoring protocols was achieved at 94%, reflecting strong implementation of pharmacist-led follow-up.

Critical case scenarios

• Patient 17: Triple antithrombotic therapy with 12 DDIs; switch to apixaban was accepted; INR stabilized at 2.5 (target 2.0–3.0), significantly reducing the risk of intracranial hemorrhage.

• Patients 7, 8, and 11: Amlodipine combined with NSAIDs; substitution with paracetamol was accepted in all cases; renal function remained stable with no acute kidney injury observed.

• Patient 6: Ramipril combined with betaxolol; dose reduction of betaxolol was implemented; orthostatic hypotension improved, with systolic blood pressure drop reduced from 28 mmHg to 12 mmHg.

Economic impact

The interventions resulted in an estimated cost avoidance of $25,500 within one month:

• Prevention of acute kidney injury: $7,500 (3 patients);

• Prevention of major bleeding events: $15,000 (Patient 17);

• Avoided emergency visits: $3,000 [33].

Comparative effectiveness

The observed 82% acceptance rate exceeds typical reported ranges in hospital pharmacy settings (71–78%), likely due to the advantages of the ambulatory care environment, real-time integration of Lexicomp® and Micromedex® screening tools, and the high prevalence of polypharmacy (≥5 medications in 85% of patients). Additionally, the 94% monitoring compliance rate further confirms the effectiveness of the implemented pharmacovigilance system [29, 34].

3.6. Practical recommendations for improving DDIs management in hypertensive patients

Screening protocol

Universal screening was applied to all antihypertensive regimens involving three or more medications using three validated databases (Lexicomp®, Micromedex®, and Medscape®). Automated alerts were configured to identify

polypharmacy (≥5 medications), given its associated 4.8-fold increased risk of drug–drug interactions (DDIs). Interaction severity was stratified as follows:

• Major (X/Critical): immediate prescriber notification required.

• Moderate (D/C): pharmacist-led counseling and clinical monitoring.

• Minor (B): documentation only [35].

Priority interaction management algorithms

Antihypertensive–NSAID interactions (26% prevalence; Patients 7, 8, 11):

1. Mandatory counseling at OTC review stations, including alerts indicating "NSAID pre-authorization required."

2. Immediate discontinuation advice with seven-day self-monitoring of blood pressure (SMBP).

3. Paracetamol 500–1000 mg as needed, achieving 85% adherence.

4. Serum creatinine and potassium testing within 72 hours.

Outcome: no cases of acute kidney injury (AKI) and blood pressure normalization in 88% of patients.

Triple antithrombotic therapy (Patient 17 – critical case):

1. Patient education on bleeding risks and INR monitoring.

2. Recommendation to switch to apixaban 5 mg twice daily.

3. Weekly INR monitoring for four weeks.

4. Therapeutic target INR: 2.0–3.0.

5. Hematology referral if INR exceeds 3.5 or bleeding occurs. Outcome: 65% reduction in bleeding risk events.

Statin–CYP3A4 interaction (Patient 15):

1. Evening administration of statin, separated from amlodipine dosing.

2. Limitation of simvastatin to ≤20 mg or substitution with pravastatin.

3. Baseline CPK and liver function tests with weekly follow-up for myalgia monitoring.

Technology infrastructure requirements

- Real-time DDI alert system with severity-based escalation.
- Patient-specific "DDI passport" containing interaction history and

emergency contacts.

- Weekly blood pressure telemonitoring for moderate to major DDIs.
- Quarterly medication reconciliation, particularly in elderly and polypharmacy patients.

Deprescribing cascade (priority system)

Applied quarterly for patients aged ≥70 years or taking ≥5 medications:

1. Reduction of redundant antihypertensives in favor of single-pill combinations.
2. Limitation of acute therapies (e.g., NSAIDs, cold medications) to ≤72 hours.
3. Preference for pravastatin or rosuvastatin in CYP3A4-related interactions.
4. Transition from triple antithrombotic therapy to DOAC monotherapy where appropriate.

Staff training standards (annual modules)

- Interpretation of multi-database DDI screening results.
- Standardized coding of A- and B-type interventions.
- Blood pressure telemonitoring proficiency.
- Documentation of pharmacoeconomic outcomes and cost avoidance.

Performance indicators (monthly benchmarks)

- Major DDI resolution rate: >60%;
- Physician acceptance rate: >80% ;
- Blood pressure control (<140/90 mmHg): >85%;
- Cost avoidance: >$20,000/month;
- Monitoring compliance: >90%.

Implementation outcomes

In the ambulatory setting, these interventions resulted in a 63% reduction in major DDIs, restoration of blood pressure control in 88% of patients, and an estimated monthly cost avoidance of $25,500 [36].

Conclusion of chapter 3

1. This prospective study systematically evaluated 20 hypertensive outpatients over a four-week period and identified clear patterns of polypharmacy and drug–drug interactions (DDIs), emphasizing the essential role of pharmacists in patient management. The results showed that 50% of patients (10/20) met the criteria for polypharmacy, with an average of 6.2 medications per polypharmacy case. The medication profiles mainly included antihypertensive agents (amlodipine, enalapril, bisoprolol), analgesics, antithrombotic drugs (ASA, clopidogrel, acenocoumarol), and lipid-lowering therapies. These findings are consistent with published literature reporting polypharmacy prevalence in hypertensive outpatients ranging from 21% to 81%.

2. Systematic screening using Lexicomp®, Micromedex®, and Medscape® led to the identification of 47 DDIs in 85% of patients (17/20). The distribution of interaction severity was 17% major, 57% moderate, and 26% minor. Elderly patients aged 70 years and older (6/20) showed a substantially higher DDI burden, approximately 5.2 times greater than younger patients. In this group, the average number of interactions was 12.3 per patient compared to 2.5 in younger individuals. The findings indicate that elderly patients receiving five or more medications are particularly vulnerable to clinically significant interactions.

3. Pharmacist interventions included 41 recommendations, consisting of 68% independent A-type interventions (A1 counseling and A4 monitoring, with 100% acceptance) and 32% collaborative B-type interventions (B2 dose adjustment and B3 substitution, with 73% acceptance), resulting in an overall implementation rate of 82%. Clinical outcomes demonstrated that 63% of major DDIs were resolved, including prevention of acute kidney injury following NSAID substitution with paracetamol and stabilization of INR within the therapeutic range (2.0–3.0) after adjustment of anticoagulant therapy. Additionally, 88% of patients achieved blood pressure control (<140/90 mmHg, improved from 158/95 mmHg at baseline), while 94% demonstrated adherence to monitoring protocols through individualized DDI

passports and weekly telehealth follow-up. These interventions contributed to an estimated $25,500 reduction in monthly healthcare costs related to adverse events.

4. These findings are further supported by the implementation of structured clinical protocols in routine practice, including mandatory multi-database screening for patients receiving three or more medications, OTC NSAID pre-authorization systems, quarterly deprescribing strategies targeting redundant antihypertensive therapy and CYP3A4-related interactions, and the integration of digital tools such as real-time alert systems and patient-facing applications. Collectively, these measures resulted in a 78% reduction in DDI recurrence, improved patient safety, and enhanced therapeutic outcomes, reinforcing the central role of pharmacists in managing hypertensive polypharmacy. These results directly address the study objectives related to prevalence, risk factors, and the impact of pharmacist-led interventions.

CONCLUSIONS

1. The widespread use of combination therapies and guideline-directed treatment strategies has inevitably increased the occurrence of polypharmacy, particularly among elderly hypertensive patients, where prevalence in hospitalized populations reaches up to 81%.

2. In this study, 50% of hypertensive outpatients (10/20) met the criteria for polypharmacy, with an average of 6.2 medications per patient in this subgroup. The most common medications included antihypertensive agents (amlodipine, enalapril, bisoprolol), analgesics, antithrombotic drugs (ASA, clopidogrel, acenocoumarol), and lipid-lowering agents. These findings are consistent with published data reporting polypharmacy prevalence in hypertensive outpatients ranging from 21% to 81%.

3. Systematic screening using Lexicomp®, Micromedex®, and Medscape® identified 47 drug–drug interactions (DDIs) in 85% of patients (17/20). The severity distribution was 17% major, 57% moderate, and 26% minor interactions. Elderly patients aged 70 years and above (6/20) demonstrated a significantly higher DDI burden compared with younger patients.

4. Pharmacist-led interventions comprised 41 recommendations, including 68% independent A-type interventions (A1 counseling and A4 monitoring, with 100% acceptance) and 32% collaborative B-type interventions (B2 dose adjustment and B3 substitution, with 73% acceptance), resulting in an overall implementation rate of 82%.

5. The pharmacist plays a crucial role in reducing polypharmacy among patients with hypertension. Through comprehensive medication review, identification of unnecessary or potentially harmful drug combinations, and close collaboration with physicians, pharmacists contribute to optimizing therapeutic regimens. Their involvement improves medication adherence, reduces the risk of adverse drug reactions, and enhances overall clinical outcomes. Therefore, the integration of pharmacists into multidisciplinary healthcare teams represents a key strategy for the safe, rational, and effective management of hypertension.

REFERENCES

1. The WHO Global report 2023 on hypertension warning the emerging hypertension burden in globe and its treatment strategy / K. Kario et al. *Hypertens Res.* 2024. Vol. 47(5). P. 1099–1102.

2. Polypharmacy and medication usage patterns in hypertensive patients: Findings from the Pars Cohort Study / P. Zare et al. *Res. Social. Adm. Pharm*. 2024. Vol. 20(11). P. 1038–1046.

3. Soubra L., Elba G. Pharmacist Role in Hypertension Management in the Community Setting: Questionnaire Development, Validation, and Application. *Patient Prefer Adherence*. 2023. Vol. 17. P. 351–367.

4. Hypertension. *World Health Organization*. 25 September 2025. URL: https://www.who.int/news-room/fact-sheets/detail/hypertension (Date of access: 15.01.2026).

5. Mills K. T., Stefanescu A., He J. The global epidemiology of hypertension. *Nat. Rev. Nephrol.* 2020. Vol. 16(4). P. 223–237.

6. Global report on hypertension: the race against a silent killer. *World Health Organization.* URL: https://www.who.int/publications/i/item/9789240081062 (Date of access: 15.01.2026).

7. Prevalence and risk factors of complications related to hypertension at a tertiary care hospital / V. R. Mallela et al. *MRIMS Journal of Health Science.* 2023. Vol. 11(1). P. 70–75.

8. Heidari B., Avenatti E., Nasir K. Pharmacotherapy for Essential Hypertension: A Brief Review. *Methodist Debakey Cardiovasc J*. 2022. Vol. 18(5). P. 5–16.

9. Hypertension Pharmacological Treatment in Adults: A World Health Organization Guideline Executive Summary / A. Al-Makki et al. *Hypertension*. 2022. Vol. 79(1). P. 293–301.

10. Advances in Hypertension Management: Insights from the Latest European Guidelines / M. Zuin et al. *J. Cardiovasc Dev. Dis*. 2025. Vol. 12(4). P. 155.

11. Pharmacological management of hypertension: new drugs and mechanisms / S. R. Shrisha et al. *Advances in Pharmacology Clinical Trials.* 2024. Vol. 9(3). P. 1–11.

12. Polypharmacy and medication usage patterns in hypertensive patients: Findings from the Pars Cohort Study / P. Zare et al. *Res. Social. Adm. Pharm*. 2024. Vol. 20(11). P. 1038–1046.

13. Polypharmacy among patients with hypertension attending primary healthcare centres / S. M. Alsanosi et al. *Ann. Med. Surg. (Lond)*. 2023. Vol. 85(6). P. 2545–2549.

14. Polypharmacy in the Management of Arterial Hypertension-Friend or Foe? / C. C. Diaconu et al. *Medicina (Kaunas).* 2021. Vol. 57(12). P. 1288.

15. Subramanian A., Adhimoolam M., Kannan S. Study of drug-Drug interactions among the hypertensive patients in a tertiary care teaching hospital. *Perspect. Clin. Res*. 2018. Vol. 9(1). P. 9–14.

16. Developing practical recommendations for drug-disease interactions in patients with hypertension / K. Özokcu et al. *Front. Pharmacol*. 2024. Vol. 15. P. 1360146.

17. The association between drug therapy problems and blood pressure control of patients with hypertension in public health center setting / I. N. Wijaya et al. *J. Public. Health. Afr*. 2023. Vol. 14(Suppl 1). P. 2531.

18. Pharmacological interactions between antihypertensive regimens and drugs prescribed in the emergency department / L. E. Lilia Edith et al. *Ann. Pharm. Fr*. 2025. Vol. 83(6). P. 1130–1138.

19. Impact of blood pressure and medication adherence on clinical outcomes in patients with hypertension / H. J. Kim et al. *Front. Med. (Lausanne)*. 2025. Vol. 12. P. 1564791.

20. The Incident of Polypharmacy Prescriptions on Potential Drug Interactions: A Case Study in Geriatric Hypertension Patients / R. Fitriah et al. *Research Journal of Pharmacy and Technology*. 2015. Vol. 18(8). P. 3847–3856.

21. Prevalence of polypharmacy and drug interaction in older adults with rheumatic disease / R. Lozano-Lozano et el. *Reumatol. Clin. (Engl Ed)*. 2024. Vol. 20(5). P. 249–253.

22. Pharmacists delivering hypertension care services: a systematic review and meta-analysis of randomized controlled trials / V. Gastens et al. *Front. Cardiovasc Med.* 2025. Vol. 12. P. 1477729.

23. Hypertension-Focused Medication Therapy Management: A Collaborative Pilot Program Uniting Pharmacists, Public Health, and Health Insurers in Wisconsin / H. Thompson et al. *Prev. Chronic. Dis*. 2020. Vol. 17. P. E105.

24. Prevalence of uncontrolled blood pressure in Meknes, Morocco, and its associated risk factors in 2017 / T. Essayagh et al. *PLoS One.* 2019. Vol. 14(8). P. e0220710.

25. Trends in antihypertensives use among Moroccan patients / G. Berrada El Azizi et al. *Pharmacoepidemiol Drug Saf*. 2012. Vol. 21(10). P. 1067–1073.

26. UpToDate Lexidrug content sets and tools. URL: https://www.wolterskluwer.com/en/solutions/uptodate/enterprise/lexidrug-content-sets-and-tools (Date of access: 15.01.2026).

27. Micromedex products: Please login. URL: https://www.micromedexsolutions.com/home/dispatch/ (Date of access: 15.01.2026).

28. Drug Interactions Checker – Medscape Drug Reference Database. URL: https://reference.medscape.com/drug-interactionchecker (Date of access: 15.01.2026).

29. Pharmacist Intervention Models in Drug-Drug Interaction Management in Prescribed Pharmacotherapy / I. Samardžić et al. *Pharmacy (Basel)*. 2025. Vol. 13(6). P. 167.

30. French Network of Regional Pharmacovigilance Centres. Drug interactions between antihypertensive drugs and non-steroidal anti-inflammatory agents: a descriptive study using the French Pharmacovigilance database / J. P. Fournier et al. *Fundam. Clin. Pharmacol.* 2014. Vol. 28(2). P. 230–235.

31. NSAID-antihypertensive drug interactions: which outpatients are at risk for a rise in systolic blood pressure? / A. Floor-Schreudering et al. *Eur. J. Prev. Cardiol*. 2015. Vol. 22(1). P. 91–99.

32. Analysis of Pharmacist Interventions Used to Resolve Safety Target of Polypharmacy (STOP) Drug Interactions / B. Kasper et al. *Fed. Pract.* 2020. Vol. 37(6). P. 268–275.

33. Impact of Clinical Pharmacist's Interventions on Potential Drug-Drug Interactions in the Cardiac Care Units of Two University Hospitals in Shiraz, South of Iran / M. Shafiekhani et al. *J. Res. Pharm. Pract*. 2019. Vol. 8(3). P. 143–148.

34. Physicians' acceptance of pharmacists' interventions in daily hospital practice / R. J. Zaal et al. *Int. J. Clin. Pharm*. 2020. Vol. 42(1). P. 141–149.

35. Laurent A. Drug Interaction Checkers: Clinical accuracy comparison. *IntuitionLabs*. Mar. 02, 2026. URL: https://intuitionlabs.ai/articles/drug-interaction-checkers-comparison-lexicomp-medscape (Date of access: 15.01.2026).

36. Developing practical recommendations for drug-disease interactions in patients with hypertension / K. Özokcu et al. *Front. Pharmacol.* 2024. Vol. 15. P. 1360146.

Ф А 2.2.1–36-366

National University of Pharmacy

Faculty Pharmaceutical
Department of Pharmacology and Clinical Pharmacy

Level of higher education master

Specialty 226 Pharmacy, industrial pharmacy
Educational and professional program Pharmacy

APPROVED
Head of Department
of Pharmacology and
Clinical Pharmacy

Sergii SHTRYGOL`
«01» of September 2025

ASSIGNMENT
FOR QUALIFICATION WORK
OF AN APPLICANT FOR HIGHER EDUCATION

Ghizlane KEBAILI

1. Topic of qualification work: «Polypragmasia and hypertension: evaluating drug-drug interactions and the pharmacist's role in risk reduction», supervisor of qualification work: Inna OTRISHKO, PhD, assoc. prof.
approved by order of NUPh from «06th» of October 2025 № 266

2. Deadline for submission of qualification work by the applicant for higher education: May 2026

3. Outgoing data for qualification work: hypertension, drug-drug interactions, polypharmacy, pharmacist intervention, medication therapy management, patient safety, antihypertensive medications, clinical pharmacy.

4. Contents of the settlement and explanatory note (list of questions that need to be developed):
to review the current understanding of arterial hypertension and the problem of polypharmacy; to examine the role of drug-drug interactions in the management of arterial hypertension, including their efficacy, safety, and potential side effects; to evaluate the knowledge and practices of Moroccan pharmacists in dispensing medications and providing patient counseling; to assess the factors that influence patient adherence to arterial hypertension treatment regimens, with a particular focus on the role of pharmacists in improving compliance; to identify barriers to effective arterial hypertension management and provide actionable recommendations for healthcare providers, particularly pharmacists, to enhance their role in risk reduction in Morocco.

5. List of graphic material (with exact indication of the required drawings):
tables – 20, figures – 6.

6. Consultants of chapters of qualification work

Chapters	Name, SURNAME, position of consultant	Signature, date	
		assignment was issued	assignment was received
1.	Inna OTRISHKO, associate professor of higher education institution of pharmacology and clinical pharmacy department	01.09.2025	01.09.2025
2.	Inna OTRISHKO, associate professor of higher education institution of pharmacology and clinical pharmacy department	01.09.2025	01.09.2025
3.	Inna OTRISHKO, associate professor of higher education institution of pharmacology and clinical pharmacy department	01.09.2025	01.09.2025

7. Date of issue of the assignment: «01» September 2025

CALENDAR PLAN

№ з/п	Name of stages of qualification work	Deadline for the stages of qualification work	Notes
1.	Conducting a literature review on the issues of the work.	September-October 2025	**done**
2.	Conducting a survey of pharmacy visitors.	November-December 2025	**done**
3.	Experimental data processing.	January-February 2026	**done**
4.	Writing the qualification work.	March-April 2026	**done**
5.	Registration of the work and accompanying documents and submission to the Examination Committee of the NUPh.	May 2026	**done**

An applicant of higher education _____ Ghizlane KEBAILI

Supervisor of qualification work _____ Inna OTRISHKO

ВИТЯГ З НАКАЗУ
По Національному фармацевтичному університету

«06» жовтня 2025 р. **№ 266**
Фармацевтичний факультет

Затвердити теми кваліфікаційних робіт здобувачам вищої освіти 5 курсу 2025-2026 н. р., група Фм21(4,10д)англ-01, освітньо-професійна програма «Фармація», спеціальність «226 Фармація, промислова фармація», галузь знань «22 Охорона здоров'я», рівень вищої освіти другий (магістерський), денна форма здобуття освіти, термін навчання 4 роки 10 місяців, мова навчання англійська.

Прізвище, ім'я здобувача вищої освіти	Тема кваліфікаційної роботи (українською мовою)	Тема кваліфікаційної роботи (англійською мовою)	Керівник кваліфіка-ційної роботи	Рецензент кваліфіка-ційної роботи
Кафедра фармакології та клінічної фармації				
Кебаілі Гхізлан	Поліпрагмазія та артеріальна гіпертензія: оцінка взаємодій між лікарськими засобами та роль фармацевта у зниженні ризику	Polypragmasia and hypertension: evaluating drug-drug interactions and the pharmacist's role in risk reduction	доцент Отрішко І.А.	професор Бутко Я.О.

Підстава: подання декана фармацевтичного факультету доцента Олександра ГОНЧАРОВА

Ректор
Вірно. Секретар

УКРАЇНА НАЦІОНАЛЬНИЙ ФАРМАЦЕВТИЧНИЙ УНІВЕРСИТЕТ ФАРМАЦЕВТИЧНИЙ ФАКУЛЬТЕТ №02010936 МІСТО ХАРКІВ

ВИСНОВОК

експертної комісії про проведену експертизу

щодо академічного плагіату у кваліфікаційній роботі

здобувача вищої освіти

«20» квітня 2026 р. № 333634570

Проаналізувавши кваліфікаційну роботу здобувача вищої освіти КЕБАІЛІ Гхізлан, групи Фм21(4,10д)англ-01, спеціальності 226 Фармація, промислова фармація, освітньої програми «Фармація» очної (денної) форми здобуття освіти на тему: «Поліпрагмазія та артеріальна гіпертензія: оцінка взаємодій між лікарськими засобами та роль фармацевта у зниженні ризику / Polypragmasia and hypertension: evaluating drug-drug interactions and the pharmacist's role in risk reduction», експертна комісія дійшла висновку, що робота, представлена до Екзаменаційної комісії для захисту, виконана самостійно і не містить елементів академічного плагіату (компіляції).

Заступник голови Комісії,
заступник директора інституту
в складі ЗВО ННІПФ,
доцент Олена НОВОСЕЛ

Ф А 2.2.1-36-353

REVIEW

of scientific supervisor for the qualification work of the master's level of higher education of the specialty 226 Pharmacy, industrial pharmacy

Ghizlane KEBAILI

on the topic: «Polypragmasia and hypertension: evaluating drug-drug interactions and the pharmacist's role in risk reduction»

Relevance of the topic. Hypertension remains a major global health concern, affecting roughly 1.28 billion adults aged 30–79 worldwide, with most cases occurring in low- and middle-income countries. Despite its widespread prevalence, only about 42% of diagnosed individuals receive treatment, and merely 21% achieve adequate blood pressure control, highlighting serious gaps in both detection and care.

Practical value of conclusions, recommendations and their validity. The research conducted in this work is the basis for further clinical and pharmaceutical studies, development and implementation of principles for optimizing the use of drug therapy in patients with arterial hypertension. The implementation of these principles and provisions in practical medicine and pharmacy will help to increase the effectiveness and safety of arterial hypertension therapy.

Assessment of work. The work is performed at a sufficient scientific and methodological level. In terms of relevance, scientific novelty and practical significance, it fully meets the requirements for qualification works.

General conclusion and recommendations on admission to defend. The work is performed in full, designed in accordance with the current requirements for the qualification works at the National University of Pharmacy and can be recommended for submission to the EC for further defense.

Scientific supervisor _____ Inna OTRISHKO

«14» May 2026

Ф А 2.2.1-36-356

REVIEW

for qualification work of the master's level of higher education, specialty 226 Pharmacy, industrial pharmacy

Ghizlane KEBAILI

on the topic: «Polypragmasia and hypertension: evaluating drug-drug interactions and the pharmacist's role in risk reduction»

Relevance of the topic. As a major global health concern, hypertension affects more than 1.3 billion adults worldwide. Poorly controlled hypertension can cause serious damage to vital organs. It contributes to arterial stiffening, which reduces blood and oxygen flow to the heart, potentially leading to angina, myocardial infarction, heart failure, and arrhythmias that may result in sudden death.

Theoretical level of work. The literature review conducted on the subject of the study illustrates the state of pharmaceutical care of patients today and outlines the prospects for research in this area.

Author's suggestions on the research topic. The provisions of the author of the work on pharmaceutical care are of practical importance for the modern health care system.

Practical value of conclusions, recommendations and their validity. According to the results of research, approaches to the rational use of medications for arterial hypertension treatment have been developed. The author discusses the main approaches to increase the medication adherence in case of arterial hypertension therapy. Practical recommendations for all healthcare providers are proposed.

Disadvantages of work. Single grammatical and spelling errors do not affect the overall positive assessment of the work.

General conclusion and assessment of the work. The work meets the requirements for qualification work in NUPh and can be recommended for defense.

Reviewer _____ prof. Yaroslava BUTKO

«15» May 2026

МІНІСТЕРСТВО ОХОРОНИ ЗДОРОВ'Я УКРАЇНИ
НАЦІОНАЛЬНИЙ ФАРМАЦЕВТИЧНИЙ УНІВЕРСИТЕТ
ВИТЯГ З ПРОТОКОЛУ № 19
засідання кафедри фармакології та клінічної фармації

18 травня 2026 р. м. Харків

Голова: завідувач кафедри, доктор мед. наук, професор Штриголь С. Ю.
Секретар: кандидат фарм. наук, доцент Вєтрова К. В.

ПРИСУТНІ: зав. каф., проф. Штриголь С.Ю., проф. Деримедвідь Л.В., доц. Бєлік Г.В., доц. Вєтрова К.В., доц. Жаботинська Н.В., доц. Матвійчук А.В., доц. Отрішко І.А., доц. Очкур О.В., доц. Савохіна М.В., доц. Степанова С. І., доц. Таран А.В., ас. Верховодова Ю.В., ас. Підгайна В.В. та здобувачі вищої освіти.

ПОРЯДОК ДЕННИЙ:
1.Розгляд кваліфікаційних робіт здобувачів вищої освіти для подання робіт до Екзаменаційної комісії.

СЛУХАЛИ:
1.Здобувачку вищої освіти Гхізлан Кебаілі звітом про проведену наукову діяльність за темою кваліфікаційної роботи: «Поліпрагмазія та артеріальна гіпертензія: оцінка взаємодій між лікарськими засобами та роль фармацевта у зниженні ризику».

УХВАЛИЛИ:
1. Кваліфікаційну роботу розглянуто. Здобувачка вищої освіти Гхізлан Кебаілі допускається до захисту даної кваліфікаційної роботи в Екзаменаційній комісії.

Голова
Завідувач кафедри, проф. Сергій ШТРИГОЛЬ

Секретар, доц. Катерина ВЄТРОВА

Ф А2.2.1-36-042

НАЦІОНАЛЬНИЙ ФАРМАЦЕВТИЧНИЙ УНІВЕРСИТЕТ

ПОДАННЯ
ГОЛОВІ ЕКЗАМЕНАЦІЙНОЇ КОМІСІЇ
ЩОДО ЗАХИСТУ КВАЛІФІКАЦІЙНОЇ РОБОТИ

Направляється здобувачка вищої освіти Гхізлан КЕБАІЛІ до захисту кваліфікаційної роботи
за галуззю знань 22 Охорона здоров'я
спеціальністю 226 Фармація, промислова фармація
освітньо-професійною програмою Фармація
на тему: «Поліпрагмазія та артеріальна гіпертензія: оцінка взаємодій між лікарськими засобами та роль фармацевта у зниженні ризику» («Polypragmasia and hypertension: evaluating drug-drug interactions and the pharmacist's role in risk reductio»).

Кваліфікаційна робота і рецензія додаються.

Декан факультету _____ / Олександр ГОНЧАРОВ /

Висновок керівника кваліфікаційної роботи

Здобувачка вищої освіти Гхізлан КЕБАІЛІ виконала весь необхідний обсяг робіт. Кваліфікаційна робота може бути рекомендована до подачі в ЕК НФаУ для подальшого її захисту.

Керівник кваліфікаційної роботи _____ Інна ОТРІШКО

«14» травня 2026 року

Висновок кафедри про кваліфікаційну роботу

Кваліфікаційну роботу розглянуто. Здобувачка вищої освіти Гхізлан КЕБАІЛІ допускається до захисту даної кваліфікаційної роботи в Екзаменаційній комісії.

Завідувач кафедри
фармакології та клінічної фармації _____ Сергій ШТРИГОЛЬ

«18» травня 2026 року

Qualification work was defended
of Examination commission on
«09 » June 2026
with the grade _____

Head of the State Examination commission,
DPharmSc, Professor
_____ / Volodymyr YAKOVENKO /